776 related articles for article (PubMed ID: 31438973)
41. Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis.
Barmak K; Harhaj EW; Wigdahl B
J Neurovirol; 2003 Oct; 9(5):522-9. PubMed ID: 13129766
[TBL] [Abstract][Full Text] [Related]
42. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation.
Harashima N; Kurihara K; Utsunomiya A; Tanosaki R; Hanabuchi S; Masuda M; Ohashi T; Fukui F; Hasegawa A; Masuda T; Takaue Y; Okamura J; Kannagi M
Cancer Res; 2004 Jan; 64(1):391-9. PubMed ID: 14729650
[TBL] [Abstract][Full Text] [Related]
43. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy.
Nakamura T
Folia Neuropathol; 2009; 47(2):182-94. PubMed ID: 19618340
[TBL] [Abstract][Full Text] [Related]
44. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders.
Azakami K; Sato T; Araya N; Utsunomiya A; Kubota R; Suzuki K; Hasegawa D; Izumi T; Fujita H; Aratani S; Fujii R; Yagishita N; Kamijuku H; Kanekura T; Seino K; Nishioka K; Nakajima T; Yamano Y
Blood; 2009 Oct; 114(15):3208-15. PubMed ID: 19666871
[TBL] [Abstract][Full Text] [Related]
45. Role of IL-21 in HTLV-1 infections with emphasis on HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Rajaei T; Farajifard H; Rafatpanah H; Bustani R; Valizadeh N; Rajaei B; Rezaee SA
Med Microbiol Immunol; 2017 Jun; 206(3):195-201. PubMed ID: 28378248
[TBL] [Abstract][Full Text] [Related]
46. High IFN-γ/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis development.
Espíndola OM; Oliveira LC; Ferreira PM; Leite AC; Lima MA; Andrada-Serpa MJ
Intervirology; 2015; 58(2):106-14. PubMed ID: 25833232
[TBL] [Abstract][Full Text] [Related]
47. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.
Tendler CL; Greenberg SJ; Blattner WA; Manns A; Murphy E; Fleisher T; Hanchard B; Morgan O; Burton JD; Nelson DL
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5218-22. PubMed ID: 2367534
[TBL] [Abstract][Full Text] [Related]
48. Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell-leukemia cells.
Kannagi M; Matsushita S; Harada S
Int J Cancer; 1993 Jun; 54(4):582-8. PubMed ID: 8514449
[TBL] [Abstract][Full Text] [Related]
49. Tumor immunity against adult T-cell leukemia.
Kannagi M; Harashima N; Kurihara K; Ohashi T; Utsunomiya A; Tanosaki R; Masuda M; Tomonaga M; Okamura J
Cancer Sci; 2005 May; 96(5):249-55. PubMed ID: 15904464
[TBL] [Abstract][Full Text] [Related]
50. Adult T-cell leukemia-lymphoma as a viral disease: Subtypes based on viral aspects.
Nosaka K; Matsuoka M
Cancer Sci; 2021 May; 112(5):1688-1694. PubMed ID: 33630351
[TBL] [Abstract][Full Text] [Related]
51. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma.
Giusti RM; Maloney EM; Hanchard B; Morgan OS; Steinberg SM; Wachter H; Williams E; Cranston B; Fuchs D; Manns A
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):699-704. PubMed ID: 8877061
[TBL] [Abstract][Full Text] [Related]
52. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
[TBL] [Abstract][Full Text] [Related]
53. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis.
Ozden S; Cochet M; Mikol J; Teixeira A; Gessain A; Pique C
J Virol; 2004 Oct; 78(19):10320-7. PubMed ID: 15367598
[TBL] [Abstract][Full Text] [Related]
54. Human T-cell lymphotropic virus type I and neurological diseases.
Nagai M; Osame M
J Neurovirol; 2003 Apr; 9(2):228-35. PubMed ID: 12707853
[TBL] [Abstract][Full Text] [Related]
55. Potential role of HTLV-1 Tax-specific cytotoxic t lymphocytes expressing a unique t-cell receptor to promote inflammation of the central nervous system in myelopathy associated with HTLV-1.
Tanaka Y; Sato T; Yagishita N; Yamauchi J; Araya N; Aratani S; Takahashi K; Kunitomo Y; Nagasaka M; Kanda Y; Uchimaru K; Morio T; Yamano Y
Front Immunol; 2022; 13():993025. PubMed ID: 36081501
[TBL] [Abstract][Full Text] [Related]
56. Human T cell lymphotropic virus type I (HTLV-I) p12I is dispensable for HTLV-I transmission and maintenance of infection in vivo.
Furukawa Y; Usuku K; Izumo S; Osame M
AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1092-9. PubMed ID: 15585100
[TBL] [Abstract][Full Text] [Related]
57. Activation and detection of HTLV-I Tax-specific CTLs by epitope expressing single-chain trimers of MHC class I in a rat model.
Ohashi T; Nagai M; Okada H; Takayanagi R; Shida H
Retrovirology; 2008 Oct; 5():90. PubMed ID: 18840303
[TBL] [Abstract][Full Text] [Related]
58. Molecular mechanisms of HTLV-1 infection and pathogenesis.
Yasunaga J; Matsuoka M
Int J Hematol; 2011 Nov; 94(5):435-42. PubMed ID: 21953273
[TBL] [Abstract][Full Text] [Related]
59. [HTLV-1-targeted immunotherapy].
Suehiro Y
Rinsho Ketsueki; 2016; 57(10):2250-2258. PubMed ID: 27795537
[TBL] [Abstract][Full Text] [Related]
60. Immunological risks of adult T-cell leukemia at primary HTLV-I infection.
Kannagi M; Ohashi T; Harashima N; Hanabuchi S; Hasegawa A
Trends Microbiol; 2004 Jul; 12(7):346-52. PubMed ID: 15223062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
